Investment Rating - The investment rating for the company is "Accumulate" [4] Core Views - The company's H1 2025 revenue was 260 million yuan, a year-on-year decline of 26.4%, with a net profit attributable to the parent company of -41 million yuan. Q2 revenue was 137 million yuan, down 25.8% year-on-year, but showed signs of improvement compared to Q1. The decline in revenue and profit was attributed to a slowdown in hospital bidding and inventory adjustments. However, H2 is expected to show recovery due to a low base and gradual commercialization of new products [1][2] - The company has launched several new products, including the AQ-400 flagship model and various endoscopes, which are expected to drive new revenue growth. The ongoing development of endoscopic surgical robots and 3D digestive endoscopes is also anticipated to contribute to long-term revenue increases [2] - The gross margin for H1 2025 was 62.4%, down 9.1 percentage points year-on-year, primarily due to an increase in overseas revenue and changes in product mix. The net profit margin is expected to remain low in 2025 but may improve in subsequent years as new products gain traction and bidding activities recover [3] Financial Summary - Revenue projections for 2025-2027 are 753 million, 944 million, and 1.157 billion yuan, with year-on-year growth rates of 0.44%, 25.41%, and 22.55% respectively. Net profit attributable to the parent company is projected to be 30 million, 107 million, and 166 million yuan for the same years, with significant growth rates of 45.12%, 249.40%, and 55.82% respectively [4][5]